Complement receptors (CR) and cytotoxic responses: monoclonal antibodies directed against CR1 and CR3 inhibit the generation of human allospecific and virus specific cytotoxic cells in vitro.

A variety of cellular immune responses involve complement factors which bind to specific receptors, and modulate or effect a specific reaction. Monoclonal antibodies (MAb) have been generated against complement receptors (CR) 1 and 3, which were utilized to investigate human allogeneic and Epstein-Barr virus specific cytotoxic cells in vitro. MAb OKM1, which binds to the C3bi CR (CR3), and MAb M710, which binds to the C3b/4b CR (CR1), inhibited the generation of both allogeneic and virus specific cytotoxic responses in vitro in a dose-dependent way; doses of 1 microgram/ml (or greater) completely abrogated the cytotoxic responses. Inhibition of these responses was observed when the MAb was added to the cultures at any time point except the last two days. In addition, treatment of the responder (but not the stimulator cells) with either MAb resulted in complete inhibition of cytotoxic responses. These experiment indicate that complement receptors participate in the generation of human cytotoxic responses in vitro.

[1]  T. Springer,et al.  Defective natural killer cytotoxicity and polymorphonuclear leukocyte antibody-dependent cellular cytotoxicity in patients with LFA-1/OKM-1 deficiency. , 1984, Journal of immunology.

[2]  T. Springer,et al.  Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis , 1984, The Journal of experimental medicine.

[3]  G. Tsokos,et al.  Modulation of human B cell immunoglobulin secretion by the C3b component of complement. , 1984, Journal of immunology.

[4]  T. Egwang,et al.  The role of complement in the induction and regulation of immune responses. , 1984, Immunology.

[5]  F. Sánchez‐Madrid,et al.  A human leukocyte differentiation antigen family with distinct alpha- subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule , 1983, The Journal of experimental medicine.

[6]  D. Fearon,et al.  Characterization of human T lymphocytes that express the C3b receptor. , 1983, Journal of immunology.

[7]  Rossi Gd Structure and function of membrane complement receptors. Summary. , 1982 .

[8]  F. Sánchez‐Madrid,et al.  LFA‐1 and Lyt‐2,3, Molecules Associated with T Lymphocyte‐Mediated Killing; and Mac‐1, an LFA‐1 Homologue Associated with Complement Receptor Function 1 , 1982, Immunological reviews.

[9]  H. Stein,et al.  Human complement (C3b) receptors defined by a mouse monoclonal antibody. , 1982, Immunology.

[10]  S. Ferrone,et al.  T lymphocyte-mediated cytotoxicity against autologous EBV-genome-bearing B cells. , 1981, Journal of immunology.

[11]  T. Hirano,et al.  In vitro induction of HLA-restricted cytotoxic T lymphocytes against autologous Epstein-Barr Virus transformed B lymphoblastoid cell line. , 1981, Journal of Immunology.

[12]  J. Weiler,et al.  The third component of complement inhibits human lymphocyte blastogenesis. , 1981, Journal of immunology.

[13]  J. Lambris,et al.  Characteristics of isolated erythrocyte complement receptor type one (CR1, C4b-C3b receptor) and CR1-specific antibodies. , 1981, Journal of immunology.

[14]  R. Genco,et al.  Inhibition of lymphocyte blastogenesis by C3c and C3d. , 1979, Journal of immunology.

[15]  J. Weiler,et al.  Complement inhibits immune responses: C3 preparations inhibit the generation of human cytotoxic T lymphocytes , 1983, European journal of immunology.

[16]  J. Cerottini,et al.  Cell-mediated cytotoxicity, allograft rejection, and tumor immunity. , 1974, Advances in immunology.